Francesco Galimi
About Francesco Galimi
Francesco Galimi serves as the Chief Medical Officer at Adicet, bringing extensive experience in medical oncology and clinical development from prestigious roles at Amgen, Inc., Onyx Pharmaceuticals, and GNF/Novartis.
Francesco Galimi Chief Medical Officer of Adicet
Francesco Galimi is the Chief Medical Officer at Adicet, a role he began in September 2019. Since joining the company, he has been instrumental in overseeing the clinical development strategies and initiatives. In this capacity, he brings his extensive experience in both clinical and early development within the oncology sector to Adicet, aligning the company's medical and research goals with industry standards and advances.
Francesco Galimi Education and Medical Expertise
Francesco Galimi completed his M.D. and subsequently earned a Ph.D. from the University of Torino Medical School, where he specialized in Medical Oncology. His advanced education solidified his foundation in medical research and clinical practice, particularly in the oncology field. This robust academic background has underpinned his career as a leading medical professional in the development of cancer treatments.
Francesco Galimi's Role at Amgen
Before joining Adicet, Francesco Galimi served as the Global Program General Manager, Early Development at Amgen, Inc. In this role, he managed global programs and was responsible for spearheading early development processes. His tenure at Amgen further honed his skills in overseeing comprehensive clinical development programs and managing large-scale projects in the pharmaceutical industry.
Francesco Galimi at Onyx Pharmaceuticals and Novartis
Francesco Galimi previously held the position of Head of Clinical Development at Onyx Pharmaceuticals, Inc., where he led clinical development strategies and execution. Additionally, he served in leadership roles at GNF/Novartis, where he was responsible for the early development of a robust portfolio of oncology programs. His leadership in these roles facilitated significant advancements in oncology research and development.